The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. (Q38163945)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

main subject

organ transplantation

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

5

Teun van Gelder

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Dennis A Hesselink

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Rachida Bouamar

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ron H N van Schaik

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

1 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

123-139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40262-013-0120-3

1 March 2020

exact match

0 references

cites work

Immunosuppression: practice and trends

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

OPTN/SRTR 2011 Annual Data Report: kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Clinical pharmacokinetics of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Mechanisms of clinically relevant drug interactions associated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Pharmacogenetic biomarkers: cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

In vitro metabolism of cyclosporine A by human kidney CYP3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Cytochrome P450 CYP3A in human renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Frequencies of CYP3A5*1/*3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Racial variation in dosage requirements of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Dosing equation for tacrolimus using genetic variants and clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Validation of tacrolimus equation to predict troughs using genetic and clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

PharmGKB summary: very important pharmacogene information for CYP3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Association of four DNA polymorphisms with acute rejection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Chronic renal failure after transplantation of a nonrenal organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Renal insufficiency after heart transplantation: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Donor ABCB1 variant associates with increased risk for kidney allograft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Chronic progressive calcineurin nephrotoxicity: an overstated concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

New-onset diabetes after kidney transplantation-changes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

A Polymorphism in the Zinc Transporter Gene SLC30A8 Confers Resistance Against Posttransplantation Diabetes Mellitus in Renal Allograft Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

TCF7L2 polymorphism associates with new-onset diabetes after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Variants of the adiponectin and adiponectin receptor-1 genes and posttransplantation diabetes mellitus in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Neurotoxicity of immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Changing picture of central nervous system complications in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

High brain densities of the immunophilin FKBP colocalized with calcineurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Impairment of the blood-brain barrier can result in tacrolimus-induced reversible leucoencephalopathy following heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 and ABCB1 genes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the Abbott immunoassay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

Mechanisms of calcineurin inhibitor-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0120-3

The genetic determinants of the CYP3A5 polymorphism

21 January 2018

1 reference

12 December 2020

Calcineurin inhibitor nephrotoxicity

1 reference

12 December 2020

Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study

1 reference

12 December 2020

A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients

1 reference

12 December 2020

Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy

1 reference

12 December 2020

The Once-Daily Formulation of Tacrolimus

1 reference

12 December 2020

Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.

1 reference

12 December 2020

P-glycoprotein expression and function in circulating blood cells from normal volunteers.

1 reference

12 December 2020

Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity

1 reference

12 December 2020

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

1 reference

12 December 2020

Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients

1 reference

12 December 2020

Calcineurin and the biological effect of cyclosporine and tacrolimus

1 reference

12 December 2020

Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation

1 reference

12 December 2020

Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients

1 reference

12 December 2020

Optimization of initial tacrolimus dose using pharmacogenetic testing

1 reference

12 December 2020

P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity

1 reference

12 December 2020

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients

1 reference

12 December 2020

Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies.

1 reference

12 December 2020

Chronic calcineurin inhibitor use is nephrotoxic

1 reference

12 December 2020

Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation

1 reference

12 December 2020

The beneficial effects of recipient-derived vascular endothelial growth factor on graft survival after kidney transplantation

1 reference

12 December 2020

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

1 reference

12 December 2020

Neurotoxicity of calcineurin inhibitors: impact and clinical management.

1 reference

12 December 2020

CYP3A5 variant allele frequencies in Dutch Caucasians

1 reference

12 December 2020

Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus

1 reference

12 December 2020

Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation

1 reference

12 December 2020

Association of Caveolin-1 Gene Polymorphism With Kidney Transplant Fibrosis and Allograft Failure

1 reference

12 December 2020

Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors

1 reference

12 December 2020

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients

1 reference

12 December 2020

Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus

1 reference

12 December 2020

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

1 reference

12 December 2020

Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection

1 reference

12 December 2020

Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients

1 reference

12 December 2020

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells

1 reference

12 December 2020

Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients

1 reference

12 December 2020

The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects

1 reference

12 December 2020

Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium

1 reference

12 December 2020

10.1007/S40262-013-0120-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24249597%20AND%20SRC:MED&resulttype=core&format=json